We're very excited to become Blue Sky's partner. The company has all of the key ingredients for success in pharma services
Worcester, MA (PRWEB) March 4, 2011
According to Paul Wengender, Founder & CEO of Blue Sky Biotech, “Blue Sky is thrilled with the partnership with Ampersand. This event forges together two successful entities with shared objectives toward strategic expansion, superior customer service, value-added technology platforms, and industry-leading cycle times.”
Peter Glick, General Partner at Ampersand Ventures, added, “We're very excited to become Blue Sky's partner. The company has all of the key ingredients for success in pharma services: strong scientific expertise, a relentless focus on service levels, and a management team deeply committed to helping biotech clients speed their development process.”
“This event enhances Blue Sky’s world-class lab operations; we are delighted to have the business acumen of Ampersand Ventures backing us.” said Dr. Norman Garceau, President & CSO of Blue Sky Biotech, Inc.
As a highlight of the partnering agreement, Peter Glick will join Blue Sky Biotech as Chairman of the Board and brings a wealth of executive experience that includes serving as President of Primedica, a pharmaceutical services business that was acquired by Charles River Labs. The company also announced that three additional new board members will be appointed in 2011.
About Blue Sky Biotech, Inc.
Blue Sky Biotech was founded in 2003 to accelerate drug discovery by offering a bundle of preclinical services that enable clients to focus on innovation. The company offers premium research services and products with a focus on augmenting data quality and accelerating client research projects. Blue Sky has a proven track record with industry leaders and serves the majority of Fortune’s Top Ten pharmaceutical firms.
About Ampersand Ventures
Ampersand is a Boston-based, middle market private equity firm with a focus in two core Sectors: Healthcare and Industrial. Within this core, Ampersand’s strategy emphasizes later stage, growth equity opportunities where we can be the first institutional investor. Ampersand’s unique blend of
venture, private equity and operating skills positions us to take an active teamwork approach in collaborating with the management teams of our portfolio companies.